Biopharmaceutical Fermentation System Market to Grow with a CAGR of 8.30% through 2028
Increasing demand for biopharmaceuticals,
technological advancements, and outsourcing trends are expected to drive the
Global Biopharmaceutical Fermentation System Market growth in the forecast
period, 2024-2028
According to TechSci Research report, “Biopharmaceutical
Fermentation System Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Biopharmaceutical
Fermentation System Market stood at USD 24.94 billion in 2022 and is
anticipated to grow with a CAGR of 8.30% in the forecast period, 2024-2028.
This can be attributed to regulatory support and compliance. Stringent regulatory
standards governing the biopharmaceutical industry have contributed to the
market's growth. Compliance with Good Manufacturing Practices (GMP) and other
regulatory requirements is essential for biopharmaceutical manufacturers. As a
result, companies invest in advanced fermentation systems to ensure product
quality and regulatory compliance.
In addition, emerging markets, particularly in
Asia-Pacific and Latin America, are witnessing increased biopharmaceutical
production. This trend is driven by economic growth, improved healthcare
infrastructure, and a rising middle-class population. As production scales up
in these regions, so does the demand for fermentation systems.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Biopharmaceutical
Fermentation System Market”
The biopharmaceutical fermentation market has been
significantly influenced by the COVID-19 pandemic. The outbreak led to an
unprecedented surge in demand for enzymes crucial for cutting-edge
point-of-care diagnostic kits and mRNA vaccines. A notable example is a report
from MassBio in December 2022, which highlighted how the pandemic intensified
the need for complex fermentation products in the pharmaceutical and
biotechnology sectors worldwide. The global community heavily relied on enzyme
supplies produced through fermentation during this period. Moreover, the
pandemic spurred the production of new biologic drugs for treating COVID-19,
amplifying its impact on market growth. For instance, in December 2021, Samsung
Biologics and AstraZeneca expanded their strategic biopharmaceutical production
partnership to include therapies for COVID-19. Additionally, the emergence of
new virus variants has accelerated vaccine production, involving crucial
fermentation steps. As seen in July 2022, CEPI allocated USD 30 million for
clinical trials of a new nanoparticle vaccine designed to protect against a
range of coronaviruses. These initiatives indicate that the studied market is
poised for growth and recovery in the upcoming years.
Furthermore, market growth is being driven by factors
such as the growing demand for biotech-based drugs and increased research and
development activities focused on creating novel biological drugs. For
instance, AbbVie's 2021 annual report highlighted the immense success of
Humira, one of the world's top-selling biotechnology drugs, accounting for USD
20.7 billion in net revenues and approximately 37% of AbbVie's total net
revenues in 2021. Globally, Humira sales saw a 4% increase in 2021 compared to
the previous year. Similarly, Merck & Co's 2021 annual report noted that
sales of Keytruda, a major biotech-based drug for the company, grew by 20% to
USD 17.2 billion, up from USD 14.9 billion in 2020. These rising sales figures
for biotech-based drugs reflect the increasing market demand for such products,
expected to drive market growth in the forecast period.
Moreover, the growing emphasis of companies on
developing innovative biological drugs is set to fuel the demand for
fermentation services and products, further propelling market expansion. As
evidenced by recent developments, in November 2022, Eikonoklastes Therapeutics,
a preclinical biotech company, partnered with Forge Biologics, a gene
therapy-focused contract development and manufacturing organization. This
collaboration aims to advance Eikonoklastes' AAV-based gene therapy, ET-101,
into clinical trials for treating amyotrophic lateral sclerosis (ALS).
Additionally, in August 2022, Sanofi and Innovent Biologics entered a strategic
collaboration to accelerate the development of two biologic oncology medicines
(tusamitamab ravtansine, SAR444245) and expand their presence in China, further
illustrating the momentum in the development of novel biological drugs and its
positive impact on the fermentation market.
The Global Biopharmaceutical Fermentation System Market
is segmented into product type, application, end user, regional distribution,
and company
Based on its product type, the chromatography segment
anticipates a substantial CAGR during the projected period. This growth is
driven by factors such as the increasing demand for innovative
biopharmaceutical drugs and the introduction of new product offerings.
The launch of new devices enhances
product availability in the market, which is poised to stimulate segment
growth. An example of this is Thermo Fisher Scientific's introduction of the
Thermo Scientific HyPeak Chromatography System in October 2021. This system is
among the pioneering single-use chromatography systems for bioprocessing,
offering a broad operational flow range from 1LPH to 1,980LPH, achieved through
a combination of pumps and fluid transfer assemblies (FTA) that enable
scalability from process development to cGMP manufacturing. Another noteworthy
release in October 2021 was Novasep's Hipersep Process M, an HPLC
chromatography system tailored for the purification of pharmaceutical molecules
like peptides, oligonucleotides, insulin, and other synthetic compounds.
Based on application, the Recombinant Proteins segment
is poised to claim a substantial market share in the Global Biopharmaceutical
Fermentation System Market during the forecast period for several compelling
reasons. First and foremost, there is a growing demand for recombinant proteins
in various therapeutic applications, driven by their efficacy and potential in
treating a wide range of medical conditions. Moreover, advancements in
biotechnology and genetic engineering have significantly enhanced the production
of recombinant proteins through biopharmaceutical fermentation systems, making
them more accessible and cost-effective. Additionally, the expansion of the
biopharmaceutical industry and the increasing investments in research and
development activities have accelerated the development of novel recombinant
protein-based drugs, further boosting the demand for biopharmaceutical
fermentation systems. These factors collectively position the Recombinant
Proteins segment as a prominent player in the biopharmaceutical fermentation
market.
Major companies operating in Global Biopharmaceutical
Fermentation System Market are:
- Agilent Technologies, Inc.
- Thermo Fisher Scientific Inc
- Lonza Group AG
- Sartorius Stedim Biotech GmbH
- Eppendorf SE
- Danaher Corp
- F Hoffmann-La Roche AG
- Nova Biomedical Corp
- Merck KGaA
- Becton Dickinson & Co
Download
Free Sample Report
Customers can also request for 10%
free customization on this report
“The global biopharmaceutical fermentation system
market is in the midst of significant transformation, driven by a convergence
of technological advancements, changing therapeutic landscapes, and
sustainability concerns. These emerging trends are reshaping the way
biopharmaceuticals are produced and setting the stage for a more efficient,
flexible, and sustainable future. As the industry continues to evolve,
companies that embrace these trends and invest in cutting-edge fermentation
systems will be better positioned to meet the growing demand for
biopharmaceuticals and drive innovation in the field. Staying ahead of these
trends will be key for manufacturers and stakeholders in the biopharmaceutical
fermentation system market,” said Mr. Karan Chechi, Research Director with
TechSci Research, a research-based management consulting firm.
“Biopharmaceutical Fermentation System Market By
Product Type (Upstream Products
(Bioreactors/Fermentors, Bioprocess Analyzers, Process Monitoring System,
Others), Downstream Products (Filtration & Separation, Chromatography,
Consumables and Accessories, Others)), By Application (Antibiotics, Recombinant
Proteins, Others), By End User (Biopharmaceutical Industries, Contract Research
Organization, Academic Research Institutes, Others), By Region, By Competition Forecast &
Opportunities, 2018-2028F”, has evaluated the future growth potential of Global
Biopharmaceutical Fermentation System Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Biopharmaceutical Fermentation System Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com